GENETIC TRANSFER OF A NONPEPTIDE ANTAGONIST BINDING-SITE TO A PREVIOUSLY UNRESPONSIVE ANGIOTENSIN RECEPTOR

Mutational analysis based on the pharmacological differences between mammalian and amphibian angiotensin II receptors (AT receptors) previously identified 7 aa residues located in transmembrane domains (TMs) III (Val-108), IV (Ala-163), V (Pro-192, Thr-198), VI (Ser-252), and VII (Leu-300, Phe-301) of the rat AT receptor type 1b (rAT(1b) receptor) that significantly influenced binding of the nonpeptide antagonist Losartan. Further studies have shown that an additional 6 residues in the rAT(1b) receptor TMs II (Ala-73), III (Ser-109, Ala-114, Ser-115), VI (Phe-248), and VII (Asn-295) are important in Losartan binding. The 13 residues required for Losartan binding in the mammalian receptor were exchanged for the corresponding amino acids in the Xenopus AT receptor type a (xAT(a) receptor) to generate a mutant amphibian receptor that bound Losartan with the same affinity as the rAT(1b) receptor (Losartan IC50 values: rAT(1b), 2.2 +/- 0.2 nM: xATa, > 50 mu M; mutant, 2.0 +/- 0.1 nM), To our knowledge, this is the first report of a gain-of-function mutant in which the residues crucial to formation of a ligand binding site in a mammalian peptide hormone receptor were transferred to a previously unresponsive receptor by site-directed mutagenesis. Ala substitutions and comparison of mammalian and amphibian combinatorial mutants indicated that TM III in the rAT(1b) receptor plays a key role in Losartan binding, Identification of residues involved in nonpeptide ligand binding will facilitate studies aimed at elucidating the chemical basis for ligand recognition in the AT receptor and peptide hormone receptors in general.